<DOC>
	<DOCNO>NCT02730208</DOCNO>
	<brief_summary>The primary purpose study evaluate treatment effect VX-661 combination ivacaftor ( VX-661/ivacaftor ) chest image endpoint use low-dose compute tomography ( LDCT ) Week 72 , evaluate safety VX-661/ivacaftor Week 72</brief_summary>
	<brief_title>A Study Evaluate Effect VX-661 Combination With Ivacaftor Chest Imaging Endpoints Subjects With Cystic Fibrosis , Homozygous F508del CFTR Mutation</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Homozygous F508del CFTR mutation Confirmed diagnosis CF Percent predict forced expiratory volume ( ppFEV1 ) â‰¥70 % predict normal age , sex , height screen . Stable CF disease judge investigator History comorbidity , opinion investigator , might confound result study pose additional risk administer study drug subject . An acute upper low respiratory infection , pulmonary exacerbation , change therapy ( include antibiotic ) pulmonary disease within 28 day Day 1 ( first dose study drug ) Pregnant nursing female . Sexually active subject reproductive potential willing follow contraception requirement . Any contraindication undergo chest imaging , per site 's institutional guideline</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>